new glp 1 agonist novo nordisk GLP-1 RA education Novo Nordisk promotes new GLP-1

Topline results announced in December 2025 were positive, showing that patients who switched from injectables to oral orforglipron maintained their weight loss

The study, which tested the drug in 529 patients with obesity and heart failure with preserved ejection fraction (HFpEF), demonstrated a 16.6-point increase at 52 weeks, with regard to the Clinical Summary Score (CSS) on the Kansas City Cardiomyopathy Questionnaire (KCCQ) a measure of symptoms of heart failure in comparison to an 8.7-point increase in the placebo group

Week 1-2: The Initial Stirrings Don't expect a dramatic shift right out of the gate

Kem Dng Trng Da 7Day Whitening Program Glutathione 700 V-Cream L mt sn phm siu hot ci thin mu da trng sng c cc c gi sn lng